
AGARWALEYE
NSEPrice History
Investment Checklist
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Trend
Price below most MAs — downtrend
Price Action
Support & Resistance Levels
Volume Analysis
Recent MA Crossovers
Recent Price Gaps
Stop Loss Levels
Fixed Risk
Technical Levels
Financials
Financial Analysis
| Metric | Mar '25 | Jun '25 | Sep '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹453.8 Cr | ₹487.4 Cr | — | ₹529.9 Cr |
| Net Profit | ₹32.6 Cr | ₹30.1 Cr | — | ₹33.7 Cr |
| EPS | — | ₹0.95 | — | ₹1.07 |
| Operating Profit | ₹142.5 Cr | ₹141.3 Cr | — | ₹154.6 Cr |
Peer Comparison
HospitalPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| APOLLOHOSP | Apollo Hospitals Enterprise Limited | ₹8,498.00 | +0.06% |
| MAXHEALTH | Max Healthcare Institute Limited | ₹1,012.45 | +0.28% |
| FORTIS | Fortis Healthcare Limited | ₹990.35 | +0.14% |
| ASTERDM | Aster DM Healthcare Limited | ₹814.95 | +0.15% |
| NH | Narayana Hrudayalaya Ltd. | ₹1,893.90 | +1.90% |
| MEDANTA | Global Health Limited | ₹1,235.10 | +0.49% |
| KIMS | Krishna Institute of Medical Sciences Limited | ₹785.10 | +2.57% |
| RAINBOW | Rainbow Childrens Medicare Limited | ₹1,365.00 | +1.87% |
| PARKHOSPS | Park Medi World Limited | ₹274.60 | +0.49% |
| HCG | Healthcare Global Enterprises Limited | ₹630.50 | +0.17% |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for AGARWALEYE
View All
Dr. Agarwal's Shares May Rally 35% on Strong Surgical Growth, Says Motilal Oswal — Check Target Price
Motilal Oswal remains bullish on Dr. Agarwal's structural growth story, backed by its leadership in the eye-care segment and a rapidly scaling surgical franchise.
Carlyle-backed Viyash Scientific buys Italy’s BioForLife for Rs 188 crore
Viyash Scientific, backed by Carlyle, is acquiring Italy's BioForLife for Rs. 188 crore. This move aims to build a leading global companion animal health business. BioForLife offers a strong presence in the Italian pet care market. The acquisition is expected to finalize in the second quarter of FY 2026-27.
Viyash Scientific to acquire Milan-based pet care company BioForLife
Viyash Scientific (Viyash), through its wholly owned subsidiary Alivira Animal Health (Alivira), has signed a binding agreement to acquire 100% stake in BioForLife Italia S.r.l. (BFL), a leading pet care company based in Milan, Italy. The acquisition, for a cash consideration of Rs 188 crore is expected to close in Q2 FY27.